Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biomaterials ; 84: 276-285, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26851392

RESUMO

The covalently modified ureido-conjugated chitosan/TPP multifunctional nanoparticles have been developed as targeted nanomedicine delivery system for eradication of Helicobacter pylori. H. pylori can specifically express the urea transport protein on its membrane to transport urea into cytoplasm for urease to produce ammonia, which protects the bacterium in the acid milieu of stomach. The clinical applicability of topical antimicrobial agent is needed to eradicate H. pylori in the infected fundal area. In this study, we designed and synthesized two ureido-conjugated chitosan derivatives UCCs-1 and UCCs-2 for preparation of multifunctional nanoparticles. The process was optimized in order to prepare UCCs/TPP nanoparticles for encapsulation of amoxicillin. The results showed that the amoxicillin-UCCs/TPP nanoparticles exhibited favorable pH-sensitive characteristics, which could procrastinate the release of amoxicillin at gastric acids and enable the drug to deliver and target to H. pylori at its survival region effectively. Compared with unmodified amoxicillin-chitosan/TPP nanoparticles, a more specific and effective H. pylori growth inhibition was observed for amoxicillin-UCCs/TPP nanoparticles. Drug uptake analysis tested by flow cytometry and confocal laser scanning microscopy verified that the uptake of FITC-UCCs-2/TPP nanoparticles was associated with urea transport protein on the membrane of H. pylori and reduced with the addition of urea as competitive transport substrate. These findings suggest that the multifunctional amoxicillin-loaded nanoparticles have great potential for effective therapy of H. pylori infection. They may also serve as pharmacologically effective nanocarriers for oral targeted delivery of other therapeutic drugs to treat H. pylori.


Assuntos
Amoxicilina/farmacologia , Quitosana/química , Helicobacter pylori/efeitos dos fármacos , Nanopartículas/química , Ureia/química , Quitosana/síntese química , Quitosana/toxicidade , Liberação Controlada de Fármacos , Citometria de Fluxo , Células HEK293 , Helicobacter pylori/crescimento & desenvolvimento , Humanos , Concentração de Íons de Hidrogênio , Microscopia Confocal , Nanopartículas/toxicidade , Nanopartículas/ultraestrutura , Polifosfatos/síntese química , Polifosfatos/química , Polifosfatos/toxicidade , Ureia/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA